1443004-16-7
Chemical Structure
Navivumab
Synonym(s): CT-P23
- CAS No.: 1443004-16-7
- Formula:N/A
- Molecular Weight:(146.6 kDa)
IUPAC Name: (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-3-yl picolinate
SMILES: [Navivumab]
Biological Activity: Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Navivumab | 99.10% | Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Current opinion in infectious diseases. 2018 Dec 1;31(6):527-34.
- [2]. Sparrow E, et al. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. 2016;34(45):5442-5448. [Content Brief]
-
[3]. Jun Hwang Keun. Identification of Off Target of CT-P22, Anti-Influenza Antibody, and Its Risk Assessment.
Keywords
